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Abstract: In this MiniReview, we provide general considerations for the planning and conduct of pharmacoepidemiological stud-
ies of associations between drug use and cancer development. We address data sources, study design, assessment of drug expo-
sure, ascertainment of cancer outcomes, confounder adjustment and future perspectives. Aspects of data sources include
assessment of complete history of drug use and data on dose and duration of drug use, allowing estimates of cumulative expo-
sure. Outcome data from formal cancer registries are preferable, but cancer data from other sources, for example, patient or
pathology registries, medical records or claims are also suitable. The two principal designs for observational studies evaluating
drug–cancer associations are the cohort and case–control designs. A key challenge in studies of drug–cancer associations is the
exposure assessment due to the typically long period of cancer development. We present methods to examine early and late
effects of drug use on cancer development and discuss the need for employing ‘lag-time’ in order to avoid reverse causation. We
emphasize that a new-user study design should always be considered. We also underline the need for ‘dose–response’ analyses,
as drug–cancer associations are likely to be dose-dependent. Generally, studies of drug–cancer associations should explore risk
of site-specific cancer, rather than cancer overall. Additional differentiation may also be crucial for organ-specific cancer with
various distinct histological subtypes (e.g., lung or ovary cancer). We also highlight the influence of confounding factors and dis-
cuss various methods to address confounding, while emphasizing that the choices of methods depend on the design and specific
objectives of the individual study. In some studies, use of active comparator(s) may be preferable. Pharmacoepidemiological
studies of drug–cancer associations are expected to evolve considerably in the coming years, due to the increasing availability of
long-term data on drug exposures and cancer outcomes, the increasing conduct of multinational studies, allowing studies of rare
cancers and subtypes of cancer, and methodological improvements specifically addressing cancer and other long-term outcomes.
Use of prescription and over-the-counter drugs represents
exogenous exposures that may result in either increase or
reduction in cancer risk. Clear associations have been estab-
lished for a number of drugs, for example, the preventive
effect of aspirin use against colorectal cancer [1,2] or the
increased risk of renal cancer with use of phenacetin [3,4].
Further, new hypotheses often arise, such as the recent con-
cerns about carcinogenic effects of lithium [5–7] and pioglita-
zone [8–12]. A significant challenge in the elucidation of drug
effects on cancer development is that the effects typically first
become manifest several years after drug initiation. The long
period of cancer development and the relatively low incidence
of most individual cancer types impede the ability of tradi-
tional pharmacovigilance systems, notably spontaneous report-
ing of adverse effects, to identify drug–cancer associations.
Consequently, analyses based on large-scale healthcare data
sets are essential to provide solid data on potential drug effects
on cancer incidence.
The public health importance of identifying carcinogenic
effects of drugs is apparent, as even small carcinogenic effects
of widely used drugs will result in many additional cancer
cases. Only about a dozen drugs have been established as ‘defi-
nitely carcinogenic to humans’ (Group 1) by the International
Agency for Research on Cancer (IARC) [13,14]. However,
about 50 drugs are currently classified as ‘possible or probably
carcinogenic’ (Group 2A/2B), and additional studies are neces-
sary to confirm or disprove these suspicions [15]. Importantly,
and often ignored, pharmacoepidemiological studies may also
substantiate lack of carcinogenicity for specific drugs. This has
considerable value by reassuring prescribers and patients of the
safety of drugs and thus promoting their appropriate use, which
may be compromised by preliminary reports of carcinogenicity
from a variety of sources, including case series, adverse event
reporting systems or animal experiments. Finally, identification
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of potential beneficial effects of drug use on cancer risk or
prognosis may provide important evidence that can be pursued
further in experimental and intervention studies, as well as pro-
vide clues to the development of new agents for medical cancer
prevention and treatment.
In the present MiniReview, we provide general considera-
tions on the conduct of pharmacoepidemiological studies of
drug–cancer associations. Importantly, while we are aiming to
describe aspects that should be considered when planning such
studies, our suggestions should be viewed as guidance rather
than as mandatory requirements. Specifically, we address
choices of (i) data sources and (ii) study design, (iii) assess-
ment of drug exposure, (iv) ascertainment of cancer outcomes,
(v) confounder adjustment and (vi) future perspectives.
Considerations Regarding Data Sources
In pharmacoepidemiological studies, the exposure is usually
not occurring as a single episode, but prolonged and variable
over time, during one or more exposure periods and thus
needs to be handled in a time-dependent manner. Therefore,
the most detailed drug use history should be sought – such as
claims data on dispensed prescriptions or population-based
prescription data from drug registries. Apart from dates of pre-
scription or dispensing, data on dose or duration are also nec-
essary to estimate cumulative exposure. In designing studies
to evaluate effects of a particular treatment on cancer inci-
dence, it should be considered that individual cancer types
have various induction and latent periods [16,17]. The relevant
exposure periods for different drugs thus vary in relation to
the time from initiation to manifest malignancy of specific
cancers (induction period) or from initiation to diagnosis (la-
tent period). While these induction and latent periods are usu-
ally unknown, long-term data on drug exposure and long
follow-up allow us to make different assumptions about the
relevant exposure periods.
Another challenge in the assessment of drug–cancer associa-
tions is the low incidence of many cancer types, thus requiring
very large sample sizes. One way to overcome this challenge
is to perform multi-site, multi-database or multinational stud-
ies. However, such initiatives involve several practical chal-
lenges, including legal issues and the lack of established
common data models.
Minimum requirement for outcome assessment is to have
individual-level data on cancer incidence. Although data from
population-based cancer registries are preferred, information
from other sources such as diagnostic or treatment records
may be sufficient. It is also important to obtain data on rea-
sons of loss to follow-up – including migration or insurance
gaps. Information on death and cause of death are helpful to
deal with competing risks. It is also essential to have informa-
tion on potentially important confounding factors. Some fac-
tors such as sex and age are necessary in all studies, while
other factors depend on the specific study objectives and
design.
As an example of registries useful for studies on drug–can-
cer associations, the Nordic countries (i.e., Denmark, Finland,
Norway, Iceland and Sweden) have nationwide registries con-
taining continuously updated, complete, individual-level data
on, for example, prescription drugs [18,19] and incident
Table 1.
The authors’ top 10 ‘suggested reading’ relevant to pharmacoepidemiological studies of drug–cancer associations (in non-prioritized order)
# Authors Title Topic Citation
01 Walker For drug-induced carcinogenesis, the observations are the
hypothesis. Invited editorial for the Mini-Symposium on
Cancer Pharmacoepidemiology
Basic concepts Ann Epidemiol 2016;
26(11):749-750
02 Pinheiro et al. Challenges in evaluating cancer as a clinical outcome in
postapproval studies of drug safety
Basic concepts Ann Epidemiol 2016;
26(11):735-740
03 Friis et al. European Code against Cancer 4th edition: Medical
exposures, including hormone therapy, and cancer
Basic concepts Cancer Epidemiol 2015;
29 Suppl 1:S107-19
04 Rivera et al. Connections between pharmacoepidemiology and cancer
biology: designing biologically relevant studies of cancer
outcomes
Exposure
ascertainment
Ann Epidemiol 2016;
26(11):741-745
05 Pottegard &
Hallas
New use of prescription drugs prior to a cancer diagnosis Reverse causation Pharmacoepidemiol Drug
Saf 2017;26(2):223-227
06 Umar et al. Future directions in cancer prevention Cancer biology Nat Rev Cancer 2012;
12 (12): 835–848
07 Rothman Induction and latent periods Induction/latency Am J Epidemiol 1981;
114(2):253-9
08 Pottegard
et al.
Identification of associations between prescribed medications
and cancer: a nationwide screening study
Hypothesis generation EBioMedicine 2016;7:73-9
09 Lund et al. The active comparator, new-user study design in
pharmacoepidemiology: historical foundations and
contemporary application
The active comparator,
new-user design
Curr Epidemiol Rep 2015;
2(4):221-228
10 St€urmer et al. Adjustments for unmeasured confounders in
pharmacoepidemiological database studies using external
information
Advanced confounder
adjustment
Med Care 2007;
45(10 Supl 2):S158-98
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cancers [20]. Demographic (including socio-economic) data
and hospital diagnoses are also available and can be used for
confounder adjustment. The unique personal identification
number, assigned to all residents in each Nordic country at
birth or immigration, allows for individual-level linkage of
registers and databases continuously over time. Key prescrip-
tion data include the Anatomical Therapeutic Chemical (ATC)
classification [21], formulation, package size and number,
number of defined daily doses (DDD) per package and date of
purchase. Further, in all Nordic countries, reporting of all inci-
dent cancer cases to cancer registries is mandatory by health-
care providers. The cancer data include the primary site of the
cancer, time of diagnosis, diagnosis code according to the
International Classification of Diseases (ICD), currently ver-
sion 10 (ICD-10) and histology and stage of the malignancy.
In the United States, the introduction of drug coverage for
older adults, Medicare Part D, in 2006 has facilitated use of
the Medicare fee-for-service data for pharmacoepidemiological
studies on cancer incidence [22,23]. The Medicare data cover
inpatient (Part A) and outpatient (Part B) diagnoses and proce-
dures, as well as prescription data at the pharmacy level (Part
D). The advantages of the US Medicare data include popula-
tion-based and nationwide coverage, size (over 20 million
older adults with fee-for-service data within Parts A, B and D
coverage), age range (generally high morbidity, drug use and
cancer incidence), low turnaround (the great majority stay in
these plans until death) and the linkage to US death data. Lim-
itations include the lack of information before age 65, issues
related to changing co-payments during the calendar year (the
‘doughnut hole’) and time to release (~18 months). Medicare
data can be linked to other data sources (e.g., the National
Death Index, cancer registries) but at considerable investment
(both time and money).
Considerations for the Choice of Study Design
The two principal observational designs relevant for studying
drug–cancer associations are the cohort design and the case–
control design. In the cohort design, drug users are compared
with non-users or users of comparator drug(s) and followed
over time with respect to the outcome of interest. In the case–
control design, persons with the outcome of interest, that is,
cancer, are compared with persons without cancer with respect
to their history of drug use. The cohort and case–control
designs are observational; that is, the researchers do not inter-
fere with the drug use of study participants but only retrieve
data on the drugs they acquire on their own initiative, the out-
come(s) of interest and potential confounding factors.
Cohort versus case–control design.
Although the case–control and cohort designs at first glance
appear to be exact opposites, the underlying concepts of the
two designs are similar, and the case–control study is best
understood as an efficient sampling of the experience underly-
ing a cohort study [24]. Specifically, the controls can be
viewed as a sample of the exposure distribution in the source
population that has not (yet) experienced the outcome of inter-
est. In a well-designed case–control study, the estimated odds
ratio provides unbiased estimates of the incidence rate ratio
that would have emerged from a cohort study in the same
source population [25]. If the case–control study is carefully
nested within the source population, incidence rates, incidence
rate differences and attributable proportions can also be esti-
mated. The cohort and case–control designs are equally vul-
nerable to the influence of unknown or imprecisely measured
confounding. While we aim to highlight the differences in the
applicability of the two designs below, we believe both
designs have merit in studies of drug–cancer associations.
There are circumstances where a cohort approach would be
most efficient. One such scenario is if the exposure is rare and
the cancer outcome is not rare among users (e.g., risk of skin
cancer among immunocompromised patients [26]). Also, if
outcomes other than cancer are of interest in the same study,
establishing a data set structured for cohort analyses will be
more efficient. Further, the cohort study is generally easier to
communicate to non-epidemiological professionals and laymen
readers than the case–control study. This not only stems from
the seemingly more straight-forward ‘prospective’ way of
assessing exposure and outcomes, but also from the cohort
study’s ability to display baseline characteristics that can even
be balanced by the use of propensity score methods [27]. A
similar description of characteristics among study subjects in a
case–control study (i.e., cases versus controls) will, as it
should, show a higher prevalence of established risk factors
among the cases, which may be erroneously perceived as a
problematic imbalance in the study [28]. Lastly, the cohort
design more readily facilitates the implementation of a new-
user design (see below) and the use of active comparators,
which can be of great value in handling of confounding within
some therapeutic areas.
In some situations, it would be more convenient to choose a
case–control rather than a cohort approach. Firstly, cancer is
usually a rare outcome. All things equal, this renders a case–
control study markedly more efficient in terms of required size
of the analytic dataset and computations than a cohort study.
It should be emphasized, though, that when using already col-
lected data (e.g., claims data), this gain in efficiency is purely
computational, not statistical, and given current computing
power often moot, even in very large databases. Secondly, a
cumulative dose–response association is important for estab-
lishing plausibility of a causal effect. In a cohort design, this
would imply that an exposed person should have his/her expo-
sure level re-classified each time he/she crosses the boundary
of an exposure level, which may be computationally demand-
ing, if not difficult. In the case–control design, the exposure
level of cases and controls could be computed once, that is,
on their index date, albeit under the assumption of no time-
varying confounding. Lastly, the establishment of one dataset
that enables investigation of various drug exposures in relation
to one (or more) cancer types is more easily performed using
a case–control approach, which is valuable in settings where
extraction of raw data is taxing in terms of time and expendi-
ture.
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New-user versus prevalent eser designs.
When assessing drug effects, including on cancer outcomes,
drug initiation is the most principled starting point [29,30].
Studying prevalent rather than new (incident) users of drugs
potentially violates several principles of causal inference, includ-
ing the absence of an underlying hypothetical intervention. As
such, using a ‘new-user’ design, that is, restricting the study
population to new users of the drug under study, should be con-
sidered [30]. The new-user design also reduces misclassification
of drug use due to left truncation of the time period used for
exposure ascertainment in prevalent users. Such misclassifica-
tion is of particular importance when a carcinogenic effect of
limited exposure needs to be assessed. Conversely, when only
distant or very long-term drug use is anticipated to influence
cancer risk, restriction to new users may hinder a meaningful
evaluation [7].
Although the new-user design is most readily implemented
in cohort studies, it may also be applied in case–control stud-
ies, by nesting these within a new-user cohorts [31]. Overall,
the potential value of employing a new-user study design,
either as the main analysis or as a sensitivity analysis, should
always be considered when conducting drug–cancer associa-
tion studies [32].
Other study designs.
The advantage of clinical trials over observational studies
is that randomization effectively addresses confounding, as
covariate balance between drug initiators and non-initiators is
guaranteed at baseline. Importantly, this balance extends to
covariates that are unmeasured or unknown at the time of the
study. The downsides of randomized clinical trials are the
prohibitive resource requirements, potential ethical and logistic
challenges, and with respect to cancer outcomes, the typically
relatively small number of outcomes. For obvious ethical rea-
sons, no randomized clinical trials have been launched with
the purpose of demonstrating a carcinogenic effect of a drug.
There are, however, some examples of trials aimed at
establishing cancer-preventive drug effects, for example, of
5a-reductase inhibitors [33,34], aspirin [35,36] and selective
COX2 inhibitors [37–39]. In addition, secondary analyses are
increasingly being conducted in clinical trials with primary
intervention outcomes other than cancer, for example, cardio-
vascular trials of aspirin use [40–43]. As the original study
materials were based on randomization, these secondary anal-
yses preserve some benefits of a clinical trial. Randomization
only removes baseline confounding, however, and treatment
changes during follow-up should generally not be ignored
when assessing cancer outcomes [44–46].
Several observational self-controlled designs have emerged
since the 1990s. These designs share the common feature of
comparing the occurrence of outcomes between exposed and
unexposed follow-up within the same individual [47].
Thereby, confounders that are stable over time are eliminated
by design. However, as they all focus on acute and transient
effects of drugs, they have little if any relevance for studying
drug–cancer associations.
Finally, ecological, or macro, designs should be mentioned.
Here, the unit of analysis is a population rather than an individ-
ual. An ecological design would for example compare the use of
a drug and a specific cancer incidence rate in one country with
another country (or region). Although often surprisingly persua-
sive for lay readers, epidemiologists generally consider ecologi-
cal designs as weak. It requires a high population attributable
proportion for an ecological design to be effective, that is, a sub-
stantial proportion of the cancer occurrence in the population
should be attributable to use of the specific drug. To our knowl-
edge, there are only few good examples of this approach within
drug–cancer epidemiology [48–50].
Considerations Regarding Assessment of Drug Exposure
For most suspected drug–cancer associations, the relevant
exposure window during carcinogenesis is unknown. If the
drug exposure influences carcinogenesis (early stage), then the
risk period would only start long after initial drug exposure. If
the drug has influence on later stages in cancer development,
the risk period would start earlier. The period between the first
occurrence of a cluster of cancer cells to a stage detectable by
screening measures or clinical symptoms is typically long, for
some cancer types up to 20–30 years [16]. Hence, it is almost
inconceivable that manifest clinical cancer can be an immedi-
ate effect of drug exposure due to the long period of develop-
ment for most cancer types. There are a few examples of
relatively rapid cancer development induced by exposure to
drug use, for example, the association between use of systemic
immunosuppressants and increased risk of non-Hodgkin’s
lymphoma and skin cancer in organ transplant recipients [51–
53]. An example of very long cancer development – about
20 years – is the association between use of diethylstilbestrol
and adenocarcinoma of the vagina and cervix [54,55].
Variability in latency of carcinogenic drug effects is often
described in terms of the drug being either a cancer ‘initiator’
or ‘promotor’. Conceptually, a cancer initiator is one that is a
contributory cause of the first clone of malignant cells,
whereas a promotor does not possess this property but acts a
contributory factor in accelerating cancer growth of an already
existing neoplastic lesion [17,56]. As such, cancer initiators
are thought as having a longer latency than promotors. How-
ever, in most drug–cancer studies, the mechanisms underlying
a potential carcinogenic or anti-neoplastic effect are unknown,
at least in terms of what stage of carcinogenesis is affected.
Consequently, a conceptual framework of potential promotors
and initiators typically provides little guidance when designing
a specific study. Nevertheless, as drugs may influence later
stages of carcinogenesis, studies monitoring drug–cancer asso-
ciations relatively shortly after initiation of drug therapy also
hold scientific value.
Lag-time.
The typically long period of cancer development and latency
of any carcinogenic or anti-neoplastic drug effects supports
implementation of a ‘lag-time period’. In practical terms, this
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means that cancer outcomes diagnosed shortly after drug initi-
ation should not be regarded as occurring during ‘exposed
time’, as these outcomes cannot meaningfully be ascribed to
the drug exposure. Correspondingly, a certain period after
drug discontinuation should be considered as time at risk. As
the lag period after drug initiation covers both induction and
latency of the specific cancer, and the lag period after drug
discontinuation primarily covers the latent period (plus any
potential carry-over effect), a longer lag period after initiation
than after discontinuation should be considered.
A second reason for lagging drug effects is the possibility
of protopathic bias (reverse causation). Consider a middle-
aged man who consults his general practitioner (GP) because
of obstructive urinary symptoms. Initially, the GP would be
likely to interpret the underlying condition as benign prostate
hyperplasia and prescribe a drug relieving the obstructive uro-
logic symptoms. However, additional diagnostic work-up may
reveal a prostate cancer as the underlying condition. As the
use of symptomatic drugs preceded the cancer diagnosis, an
apparent association between these drugs and prostate cancer
would emerge. In most cases, however, such reverse causation
has a time frame of <6 months [57].
The typically long induction and latent periods, the possibil-
ity of reverse causation and the likely higher probability to
detect prevalent pre-clinical cancer due to medicalization
around treatment initiation are the main reasons for employing
a lag-time in drug–cancer analyses. Reverse causation justifies
a lag-time in the order of minimum a few months [57]. The
optimal time frame for addressing the long induction and
latent periods is unknown and depends on the specific drug–
cancer association being studied. However, for most drug–
cancer associations, it is likely considerably longer than the
period necessary to address reverse causation. Acknowledging
the uncertainty surrounding the mechanisms of single drug–
cancer associations, and thus the optimal (biologically
relevant) lag-time, studies should generally evaluate various
lag periods in sensitivity analyses [58].
Dose–response association.
Most known drug–cancer associations are dependent on cumu-
lative amount, that is, stronger associations with higher
dosages and longer-term use. This may be expressed either by
cumulative duration of drug use, by cumulative quantity of the
drug or by the prescribed daily dose (coupled to duration of
use). The choice is often driven by the available data, but
mechanistic considerations are also relevant. If it is believed
that the dose intensity, that is, the daily dose, is less important,
it would be most appropriate to perform analyses according to
the cumulative duration. If the dose intensity does matter, then
the cumulative quantity or if feasible a direct measure of
intensity over time would be more appropriate. Regardless of
the measure used, dose–response or duration of use analyses
should always be carried out.
When interpreting dose–response analyses, special atten-
tion should be paid to trivial, low-level exposure. If very
low exposure shows an association with cancer, there is a
chance that the association is explained by confounding
[59,60]. While a dose–response pattern is generally consid-
ered supportive of causality, caution is advised as some
confounders may act in a graded fashion. As an example,
progressively heavier use of bronchodilators will likely cor-
relate to smoking history and thereby show a confounded
but dose-dependent association with lung cancer risk. Lastly,
another good reason for analysing cumulative dose–response
effects is that associations that are explained by reverse cau-
sation often have an inverse cumulative dose/duration–re-
sponse association and thereby can be distinguished from
causal effects.
Defining treatment episodes.
Constructing treatment episodes for study subjects from pre-
scription registries may be challenging. If prescription data do
not include information on the prescribed dose and duration of
a specific treatment, treatment episodes need to be estimated
on the basis of purchasing dates and quantities of drug pre-
scribed. In the attempt to construct treatment episodes, investi-
gators encounter temporal gaps and overlaps among
prescriptions, and different methods accounting for various
prescription patterns may lead to different estimates of drug
effects [61,62]. As there is typically long latency between the
relevant drug exposure and cancer diagnosis, such considera-
tions of the precise period of drug intake may be less impor-
tant in cancer pharmacoepidemiology than in studies of acute
or semi-acute outcomes. Nevertheless, varying prescription
patterns without specific knowledge of dose or duration of
treatment introduces an additional source of uncertainty
regarding exposure ascertainment, and researchers are, for this
and the aforementioned reasons, encouraged to apply different
exposure measures in individual studies.
Considerations Regarding Cancer Outcome Ascertainment
Important objectives of cancer classification and registration
are to assemble and compare cancer incidence data across
populations and countries, and to provide valid cancer diag-
noses for specific research purposes in analytical studies. Dur-
ing the last two decades, official cancer registration and
establishment of cancer registries have increased steadily
worldwide, substantially facilitating epidemiological and other
cancer research [63]. Valuable sources of international cancer
incidence data include the United States’ SEER program [64];
the NORDCAN program covering Scandinavian countries
[20]; and the GLOBOCAN program estimating cancer inci-
dence and mortality data on a global scale [65].
Traditionally, the most important diagnostic and clinical
modalities used to establish cancer diagnoses are reports from
pathology departments (providing histological diagnoses), hos-
pital records and death certificates, although the proportion of
cancer cases identified solely by death certification is low
today in most countries [63]. Together, clinical and histologi-
cal diagnoses provide a high level of precision in the diagno-
sis. However, access to records from radiotherapeutic and
oncology departments, medical records, imaging measures and
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haematology laboratories can also provide important informa-
tion, for example, for diagnosis of brain and other tumours of
the central nervous system and for haematological malignan-
cies. In general, completeness and validity of cancer registra-
tion increase with the number of modalities used to ascertain
the diagnoses; and significant omissions may raise concerns
that case finding is incomplete. Use of multiple sources of
cancer ascertainment demands efficient registration procedures
to ensure that all records pertaining to the same case are com-
bined into a single registration [66].
In the absence of data from cancer registries, claims-based
algorithms can be developed to identify cancer incidence.
These algorithms usually cover a combination of diagnostic
codes, procedures and take relative timing of these into
account. They need to be validated against a gold standard
(usually cancer registry data), ideally in a similar population
to the one studied. Examples include the commonly used algo-
rithms published by Setoguchi et al. [67] that showed high
specificity of a definition using two specific cancer codes
within 2 months for a variety of cancers. These algorithms are
relatively crude, however, and more work is needed to refine
and extend them to specific populations.
Using ‘cancer overall’ as outcome should be discouraged,
as this essentially goes against our understanding of cancer
as a heterogeneous disease [56]. It is inconceivable that a
pharmaceutical agent should act as a universal carcinogen, as
not even strong carcinogens, such as tobacco smoking and
radiation, are universally carcinogenic [13]. An analysis of
cancer overall is essentially driven by the effect of the drug
on the cancers with the highest incidence. Currently, cancer
diagnoses are most often classified according to organ site,
using ICD diagnostic codes. However, in continuation of
aspects of specificity, it is unlikely that a given drug would
induce all types of cancers, even within the same organ.
Thus, if feasible, differentiation according to histological sub-
types should be employed in studies of drug–cancer associa-
tions. Consider immunosuppressants that are known to
induce skin cancer; currently, there is only firm evidence that
the association pertains to non-melanoma skin cancer, not
melanomas [14]. In some organs, for example, the prostate
or colorectum, one histological type (adenocarcinoma) com-
prises most cancer cases, and as such restriction to adenocar-
cinomas makes little difference, although it should still be
carried out, if feasible. However, at many cancer sites, for
example, oesophagus, lung, breast, ovary, testis and kidney,
differentiation into distinct histologic subtypes is important,
as an analysis lumping together all histological cancer types
would be driven by the effect of the drug on the most preva-
lent subtype.
Increasing knowledge of the epidemiology, histopathology
and today also molecular profiles of cancer diseases will facili-
tate even more detailed classifications categorizing subtypes of
cancer both within and across organ sites. Identification of
more ‘refined’ cancer subtypes may thereby, in the years to
come, increase the specificity of risk associations and predic-
tions. While beyond the scope of the present MiniReview,
readers interested in the application of molecular biology in
cancer classification are referred to reviews specifically
addressing this issue [68–70].
Considerations Regarding Confounder Adjustment
Adjustment for confounding in drug–cancer association stud-
ies should generally follow the same principles as in any
other pharmacoepidemiological study. As one noticeable
exception, the assessment of confounder variables should take
into account the induction/latency period of cancer outcomes,
as discussed above. If, for example, no lag-time is considered
in the assessment of baseline or time-varying covariates, early
symptoms of a cancer or other effects of the increased medi-
cal attention preceding a cancer diagnosis may inadvertently
be included in the adjustment model. This is especially
important in case–control studies, where confounders are
often defined on the index date. Further, it is important to
emphasize that while many databases used for drug–cancer
studies lack information on important and well-established
cancer risk factors, for example, family history, many of
these will have no apparent effect on the prescribing of the
majority of drugs and thus will confer no confounding effect
in drug–cancer association studies.
Active comparator.
Important unmeasured covariates, like for example body
mass index (BMI), can sometimes be balanced by study
design rather than by statistical control. Take as an example
a study on the effects of insulin glargine on cancer out-
comes (including colorectal cancer, for which BMI is a risk
factor). In this study, BMI would be an obvious confounder
if we compared patients initiating insulin glargine with non-
initiators, because a high BMI is one of the main reasons
to initiate insulin therapy in patients with type 2 diabetes.
However, using an active comparator, human NPH insulin,
the confounding potential of BMI is mitigated because BMI
does not affect the choice of insulin after the indication for
adding insulin has been made [71]. This highlights the value
of the active comparator new-user cohort study design to
reduce the potential for unmeasured confounding. Subtle dif-
ferences in the indication of comparator drugs might still
exist and would need to be controlled for by standard ana-
lytical techniques. It is important to point out that with an
active comparator, the scientific question is changed from
absolute effects (e.g., safety) to effects relative to a clinical
alternative. The above example of a study with active com-
parator does not answer the question whether adding insulin
in patients with type 2 diabetes increases the risk of col-
orectal cancer, but the question whether the effect of insulin
glargine on colorectal cancer is different from the effect of
NPH insulin. As such, if the active comparator has the
same potential to cause cancer, for example, through a
shared pharmacological action, a carcinogenic effect might
be missed. Lastly, the idea of an active comparator should
not be pursued at all costs, but only if a suitable active
comparator can be identified, that is, a drug with
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comparable indications. If the drug under study is the first-
line treatment for mild disease, using an active comparator
that is only used as a second-line treatment or for more
severe disease might introduce more bias than it removes.
Time-varying confounding.
While confounding at drug initiation can often be limited by
study design (and remaining confounding removed during
analysis), the time-varying confounding affecting drug persis-
tence and changes in treatment over time is related to (lack
of) effectiveness and side effects. Unfortunately, many reg-
istries that contain necessary data on drug prescribing do not
contain much information (if any) on (immediate) effective-
ness and (subtle) side effects. For example, many databases
do not include measures of glucose control or other markers
of diabetes severity that may affect persistence on antidia-
betic drugs and risk of some cancers [72]. Confounding from
disease severity can bias a study in either direction. On one
hand, more severe disease may be associated with longer
duration or higher intensity of treatment. Conversely, severe
disease may also be associated with switching and thus
shorter duration of first-line treatments [73]. If good data on
the drivers of adherence/persistence are available in a data-
base, methods that allow for control for time-varying con-
founders affected by prior treatment should be used to
reduce bias [74].
Future Perspectives
The study of drug–cancer associations is in many respects still
in its infancy, and the field will likely evolve considerably
over the years to come. Three drivers of this evolution deserve
to be highlighted. Firstly, the accumulation of long-term data
on drug use and cancer incidence is of particular value in
studies of cancer aetiology, keeping in mind the potentially
long induction periods of cancer development. For example,
the Swedish Prescribed Drug Registry, covering the entire
population of Sweden (approximately 10 million inhabitants),
was established in 2005 [75], and in the United States, drug
coverage (part D) for the Medicare population was introduced
in 2006. These databases have thus only recently achieved an
age where they begin to contribute meaningfully to the field
of drug–cancer studies. Secondly, as the pharmacoepidemio-
logical community accumulates experience in conducting
multinational studies, the door is open for the study of rare
types of cancers (or drug exposures). Lastly, methodological
work, specifically addressing studies of long-term outcomes, is
both needed and ongoing. For example, further research on
the implementation of advanced methods, such as marginal
structural models or structural nested failure time models, is
needed to properly adjust for time-varying factors [76,77].
These three drivers, coupled with other emerging opportuni-
ties, such as incorporation of genetic data, clearly indicate that
we will be able to perform more comprehensive drug–cancer
association studies in the future, to secure the safe use of
drugs in the population and potentially identify new therapeu-
tic avenues for cancer prevention and treatment.
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